skip to Main Content

Dr. O’Reilly on the Utility of PARP Inhibitors in Pancreatic Cancer

Dr. O’Reilly on the Utility of PARP Inhibitors in Pancreatic Cancer
In December 2019, the FDA approved olaparib (Lynparza) for frontline maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.

This approval is important for this subset of patients with BRCA-mutant pancreatic cancer, says O’Reilly. Further research may show that combination therapy with PARP inhibitors is beneficial for patients with other DNA damage repair pathway gene mutations or somatic mutations. Watch here . . .


Back To Top